Getinge AB ( (GNGBY) ) has released its Q4 earnings. Here is a breakdown of the information Getinge AB presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Getinge AB is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. The company is known for its innovative solutions in areas like acute care therapies, life science, and surgical workflows.
Getinge AB’s financial performance for 2024 showed significant growth with record sales and improved margins. The company’s strategic initiatives and acquisitions have contributed to a robust performance, with notable increases in order intake and net sales across various regions and product categories.
Key financial highlights include a 9.2% increase in net sales and a 19.4% rise in adjusted EBITA for the year. The company also reported a strong free cash flow and proposed a dividend increase. Strategic moves, such as the acquisition of Paragonix Technologies and the decision to phase out the Surgical Perfusion product category, are expected to enhance long-term growth and profitability.
Looking ahead, Getinge anticipates continued growth in 2025 with an expected organic net sales increase of 2-5%. The company’s focus on structural improvements and strategic reallocations positions it well to navigate potential geopolitical uncertainties and leverage ongoing healthcare investments.
